Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 1
1985 1
1987 1
1988 2
1989 1
1990 2
1991 1
1992 3
1993 1
1994 2
1995 3
1996 4
1997 1
1998 1
1999 5
2000 2
2001 5
2002 1
2003 4
2004 3
2005 4
2006 2
2008 9
2009 11
2010 9
2011 5
2012 5
2013 7
2014 5
2015 5
2016 6
2017 7
2018 9
2019 19
2020 15
2021 16
2022 16
2023 9
2024 17
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Kudo M, et al. Among authors: isoda n. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. Gut. 2020. PMID: 31801872 Free PMC article. Clinical Trial.
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y. Kudo M, et al. Among authors: isoda n. Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul. Liver Cancer. 2022. PMID: 35978604 Free PMC article.
Cocirculation of Genetically Distinct Highly Pathogenic Avian Influenza H5N5 and H5N1 Viruses in Crows, Hokkaido, Japan.
Hew YL, Hiono T, Monne I, Nabeshima K, Sakuma S, Kumagai A, Okamura S, Soda K, Ito H, Esaki M, Okuya K, Ozawa M, Yabuta T, Takakuwa H, Nguyen LB, Isoda N, Miyazawa K, Onuma M, Sakoda Y. Hew YL, et al. Among authors: isoda n. Emerg Infect Dis. 2024 Sep;30(9):1912-1917. doi: 10.3201/eid3009.240356. Epub 2024 Aug 6. Emerg Infect Dis. 2024. PMID: 39106453 Free PMC article.
Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infection.
Kanda T, Li TC, Takahashi M, Nagashima S, Primadharsini PP, Kunita S, Sasaki-Tanaka R, Inoue J, Tsuchiya A, Nakamoto S, Abe R, Fujiwara K, Yokosuka O, Suzuki R, Ishii K, Yotsuyanagi H, Okamoto H; AMED HAV and HEV Study Group. Kanda T, et al. Hepatol Res. 2024 Aug;54(8):1-30. doi: 10.1111/hepr.14062. Epub 2024 Jun 14. Hepatol Res. 2024. PMID: 38874115
Environmental and host factors underlying tick-borne virus infection in wild animals: Investigation of the emerging Yezo virus in Hokkaido, Japan.
Ito M, Minamikawa M, Kovba A, Numata H, Itoh T, Ariizumi T, Shigeno A, Katada Y, Niwa S, Taya Y, Shiraki Y, Pandey GS, Nonaka N, Nakao R, Omori R, Ohari Y, Isoda N, Shimozuru M, Tsubota T, Matsuno K, Sashika M. Ito M, et al. Among authors: isoda n. Ticks Tick Borne Dis. 2024 Nov;15(6):102419. doi: 10.1016/j.ttbdis.2024.102419. Epub 2024 Nov 29. Ticks Tick Borne Dis. 2024. PMID: 39612598 Free article.
204 results